LONDON, England, April 9 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

* Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP

* Approval based on ANCHOR trials showing clinically meaningful and statistically significant improvements in nasal polyp siz . . .

Click here for more information about our products